CVE:BCT BriaCell Therapeutics (BCT) Stock Price, News & Analysis → We’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How) (From Paradigm Press) (Ad) Free BCT Stock Alerts C$10.60 -0.42 (-3.81%) (As of 12/30/2021) Add Compare Share Share Today's RangeC$10.60▼C$11.0750-Day RangeC$10.60▼C$10.6052-Week RangeC$3.50▼C$15.75Volume3,402 shsAverage Volume12,671 shsMarket CapitalizationC$168.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BriaCell Therapeutics alerts: Email Address Ad Porter & CompanySecret energy grid to power millions of homesThis high-security, secret U.S. facility has 2,100 engineers, machinists, and technicians building a new type of energy system the world has never seen before.Click here to get all the details. About BriaCell Therapeutics Stock (CVE:BCT)BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.Read More BCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCT Stock News HeadlinesFebruary 29, 2024 | ca.finance.yahoo.comBriaCell Therapeutics Corp. (BCT.TO)February 7, 2024 | msn.comBriaCell shares rise on strong data from breast cancer treatment studyFebruary 7, 2024 | markets.businessinsider.comBriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder CaseFebruary 6, 2024 | marketwatch.comBriaCell Shares Advance as Production of Lead Candidate BeginsDecember 28, 2023 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer PatientsDecember 28, 2023 | markets.businessinsider.comBriaCell's Bria-IMT Regimen Shows 71% Intracranial ORR In Breast Cancer PatientsDecember 20, 2023 | markets.businessinsider.comBriaCell Therapeutics Reports Preliminary Survival Benefit Data In Bria-IMT RegimenDecember 1, 2023 | finance.yahoo.comHere's Why We're Watching BriaCell Therapeutics' (TSE:BCT) Cash Burn SituationNovember 3, 2023 | finance.yahoo.comBriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ INDOctober 18, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp flat on Tuesday (BCT)October 6, 2023 | stockhouse.comBriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Breast CancerOctober 3, 2023 | finance.yahoo.comBriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast CancerSeptember 27, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp up on Tuesday (BCT)September 8, 2023 | markets.businessinsider.comBriaCell Therapeutics (BCT) Initiated with a Buy at H.C. WainwrightAugust 17, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp down on Wednesday (BCT)August 16, 2023 | finance.yahoo.comBriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS™ Immunotherapy for CancerMay 30, 2023 | finance.yahoo.comBriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDailyMay 25, 2023 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.May 6, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp down on Friday (BCT)April 26, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp down on Tuesday (BCT)April 25, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp down on Monday (BCT)April 21, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp up on Thursday (BCT)April 17, 2023 | baystreet.caPositive Developments for Breast Cancer Care Attracting Big Investor AttentionApril 15, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp up on Friday (BCT)April 13, 2023 | theglobeandmail.comClosing Bell: Briacell Therapeutics Corp up on Wednesday (BCT)See More Headlines Receive BCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:BCT CUSIPN/A CIKN/A Webwww.briacell.com Phone+1-604-9211810FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio129.63 Quick Ratio128.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$3.34 per share Price / Cash Flow3.17 Book ValueC$3.60 per share Price / Book2.94Miscellaneous Outstanding Shares15,913,000Free FloatN/AMarket CapC$168.68 million OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. William V. Williams M.D. (Age 65)CEO, Pres & Director Comp: $283.44kDr. Charles Louis Wiseman M.D. (Age 75)FACP, Founder Comp: $73.1kMr. Gadi Levin B.Com. (Age 48)C.A., M.B.A., CPA, MBA, CFO & Corp. Sec. Comp: $52.5kMs. Farrah DeanMang. of Corp. Devel.Key CompetitorsProMetic Life SciencesTSE:PLIVIVO CannabisCVE:ABCNFennec PharmaceuticalsTSE:FRXEmblemCVE:EMCMedicenna TherapeuticsTSE:MDNAView All Competitors BCT Stock Analysis - Frequently Asked Questions How have BCT shares performed in 2024? BriaCell Therapeutics' stock was trading at C$10.60 at the beginning of 2024. Since then, BCT stock has increased by 0.0% and is now trading at C$10.60. View the best growth stocks for 2024 here. What other stocks do shareholders of BriaCell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other BriaCell Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Gene Biotherapeutics (CRXM), Organovo (ONVO), Anavex Life Sciences (AVXL), Actinium Pharmaceuticals (ATNM), Cytokinetics (CYTK), Genmab A/S (GNMSF), Inovio Pharmaceuticals (INO), Medidata Solutions (MDSO). How do I buy shares of BriaCell Therapeutics? Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:BCT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.